Statins, cholesterol depletion and risk of incident diabetes

International Journal of Cardiology

Volumn 152, Issue 2, 2011, Pages 275-276

  Mascitelli, Luca ^a   Goldstein, Mark R ^b  

^a Medical Service   (Italy)

^b NCH Healthcare Group   (United States)

Author keywords

Cholesterol; Diabetes; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; ROSUVASTATIN;

DIABETES MELLITUS; DIABETOGENESIS; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; DRUG USE; HUMAN; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); HYPERLIPIDEMIA; META ANALYSIS (TOPIC);

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; META-ANALYSIS AS TOPIC;

EID: 84857388363     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.08.023     Document Type: Article

References (18)

1. G. Wainwright, L. Mascitelli, and M.R. Goldstein Cholesterol lowering therapies and membrane cholesterol. Stable plaque at the expense of unstable membranes? Arch Med Sci 5 2009 289 295
2. E. Ikonen Cellular cholesterol trafficking and compartmentalization Nat Rev Mol Cell Biol 9 2008 125 138 (Pubitemid 351158918)
3. F. Xia, L. Xie, and A. Mihic Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells Endocrinology 149 2008 5136 5145
4. L. Mascitelli, F. Pezzetta, and M.R. Goldstein Does intensive cholesterol lowering increase the risk of diabetes? Int J Clin Pract 63 2009 1808
5. L. Mascitelli, F. Pezzetta, and M.R. Goldstein Statins and risk of incident diabetes Lancet 375 2010 2140 2141
6. H. Kolb, and T. Mandrup-Poulsen An immune origin of type 2 diabetes? Diabetologia 48 2005 1038 1050 [Erratum in: Diabetologia 2005; 48: 1677] (Pubitemid 40909636)
7. P.O. Bonetti, L.O. Lerman, C. Napoli, and A. Lerman Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 24 2003 225 248 (Pubitemid 36207079)
8. D.J. Freeman, J. Norrie, and N. Sattar Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 2001 357 362 (Pubitemid 32105973)
9. A. Keech, D. Colquhoun, and J. Best Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial Diabetes Care 26 2003 2713 2721 (Pubitemid 37205536)
10. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
11. D. Preiss, S.R. Seshasai, and P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
12. C.P. Cannon, E. Braunwald, and C.H. McCabe Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 495 504
13. J.A. de Lemos, M.A. Blazing, and S.D. Wiviott Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316 (Pubitemid 39223221)
14. J.C. LaRosa, S.M. Grundy, and D.D. Waters Treating to New Targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435 (Pubitemid 40471450)
15. T.R. Pedersen, O. Faergeman, and J.J. Kastelein Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445 (Pubitemid 41627921)
16. J. Armitage, L. Bowman, and K. Wallendszus Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
17. K. Bouillon, A. Singh-Manoux, and M. Jokela Decline in low-density lipoprotein cholesterol concentration: lipid-lowering drugs, diet, or physical activity? Evidence from the Whitehall II study Heart 97 2011 923 930
18. G. Danaei, M.M. Finucane, and Y. Lu National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 2011 31 40